
Actinogen Medical Ltd.
Ticker: ASX: ACW
Sydney, Australia

FOR BUSINESS DEVELOPMENT, LICENSING & INVESTMENT

Ticker: ASX: ACW
Sydney, Australia


Suresnes, France


Ticker: CGTX
Purchase, United States
Cognition Therapeutics, Inc. ($CGTX) is a clinical-stage biopharmaceutical company with 20 years of mechanistic, translational, and clinical research across neurodegenerative diseases. Zervimesine (CT1812) is an investigational, first-in-class oral therapy with a unique disease-modifying mechanism of action that displaces toxic protein oligomers from neuronal receptors.
The company has prioritized development of zervimesine in dementia with Lewy bodies (DLB). Cognition and the U.S. FDA have reached alignment on key elements of a Phase 3 study in DLB including patient selection, dose, duration, and endpoints. The company expects to commence the study mid-2027. Cognition plans to use a neuropsychiatric inventory that measures hallucinations and delusions (NPI‑2) as a primary endpoint. A key secondary endpoint will be the ADCS-ADL, which will evaluate zervimesine’s treatment impact on daily function.




Kensington, United States
Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.
Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.
Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.
Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.


Rockville, United States


Genoa , Italy
IAMA Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative treatments for central nervous system disorders. The lead compound, IAMA-6, is a selective NKCC1 inhibitor designed to restore chloride homeostasis and rebalance GABAergic signaling. The mechanism has been studied in multiple CNS disorders, including Neurodevelopmental Disorders, such as Fragile X, Down Syndrome and Autism Spectrum disorders, and psychiatric and neurological conditions.
With a successfully completed phase 1 study, IAMA-6 is progressing to a Phase 2a proof of concept study in Fragile X which will be initiated late 2026.
IAMA is funded through phase 2 and is seeking funds to expand the clinical development program.

MATARO, Spain
Spain

South San Francisco, United States



Switzerland
Switzerland

Ticker: [EPA:ALTHX]

United States


South San Francisco, United States



San Diego, United States


Ticker: EPA: GNRO
PLan-les-Ouates, Switzerland


Geneva, Switzerland


Watertown, United States


CAEN, France




Dublin, Ireland










Tampa, United States
Psilera is a biopharmaceutical company developing groundbreaking therapeutics for CNS disorders.
Psilera has built a leading pipeline of next-generation neuroplastogens, including PSIL-006, a first-in-class therapeutic neuroplastogen.
With a deep commitment to scientific excellence and patient centricity, Psilera strives to provide treatment options to underserved patient populations worldwide. Welcome to the new era of mindful medicine. For more information, visit www.psilera.com.

United States
United States
Australia

Viken, Sweden


